Abstract | INTRODUCTION: EVIDENCE ACQUISITION: EVIDENCE SYNTHESIS: CONCLUSIONS: Patients treated with tofacitinib should be monitored for herpes zoster, malignancies, blood clots, and changes in laboratory values. Overall, tofacitinib is a useful new systemic agent in the treatment of psoriatic disease. Its oral route of administration, novel JAK pathway target, short half-life, and strong recapture rates after treatment interruption make it a unique new tool for psoriatic disease management. Further long-term studies will help determine its role in the treatment algorithm for psoriatic arthritis and its indication for plaque psoriasis.
|
Authors | Arvin Ighani, Jorge R Georgakopoulos, Jensen Yeung |
Journal | Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
(G Ital Dermatol Venereol)
Vol. 155
Issue 4
Pg. 400-410
(Aug 2020)
ISSN: 1827-1820 [Electronic] Italy |
PMID | 32348084
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Janus Kinase Inhibitors
- Piperidines
- Pyrimidines
- tofacitinib
- Adalimumab
- Etanercept
|
Topics |
- Adalimumab
(administration & dosage)
- Administration, Oral
- Arthritis, Psoriatic
(drug therapy, pathology)
- Etanercept
(administration & dosage)
- Humans
- Janus Kinase Inhibitors
(administration & dosage, adverse effects, pharmacology)
- Piperidines
(administration & dosage, adverse effects, pharmacology)
- Psoriasis
(drug therapy, pathology)
- Pyrimidines
(administration & dosage, adverse effects, pharmacology)
|